Table4 Clinical trials of CD47 BsAb in solid tumors
From: Targeting macrophages: a novel treatment strategy in solid tumors
BsAb | IgG subclass | Target | Conditions | Monotherapy or Combination | Number of patients recruited | Phases stage | Clinical trial NO |
|---|---|---|---|---|---|---|---|
HX009 | IgG4 | CD47 +  PD-1 | Advanced solid tumor | Monotherapy | 21 participants | Phase I | NCT04097769 |
| Â | Â | Â | Advanced solid tumor | Monotherapy | 210 participants | Phase II | NCT04886271 |
IBI322 |  | CD47 +  PD-L1 | Advanced solid tumor | Monotherapy | 36 participants | Phase I | NCT04912466 |
| Â | Â | Â | Advanced malignant tumors lymphomas | Monotherapy | 51 participants | Phase I | NCT04338659 |
| Â | Â | Â | Advanced malignancies | Monotherapy | 218 participants | Phase I | NCT04328831 |
| Â | Â | Â | Small cell lung cancer | Combination | 40 participants | Phase II | NCT05296603 |
| Â | Â | Â | Non small cell lung cancer | Combination | 80 participants | Phase II | NCT05296278 |
| Â | Â | Â | Myeloid tumor | Combination | 124 participants | Phase I | NCT05148442 |
6MW3211 |  | CD47 +  PD-L1 | Advanced malignant neoplasm | Monotherapy | 272 participants | Phase I/II | NCT05048160 |
PF-07257876 | IgG1 | CD47 +  PD-L1 | NSCLC SCCHN and ovarian cancer | Monotherapy | 90 participants | Phase I | NCT04881045 |
IBC0966 |  | CD47 +  PD-L1 | Advanced malignant tumors | Monotherapy | 228 participants | Phase I/II | NCT04980690 |
IMM2902 | IgG1 | CD47 +  HER2 | HER2 + advanced solid tumors | Monotherapy | 40 participants | Phase I | NCT05076591 |